#1 Clinical Trials Search in Europe

Emavusertib

Emavusertib, also known as CA-4948, is an innovative drug being studied in clinical trials for the treatment of various hematologic malignancies, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and primary central nervous system lymphoma (PCNSL). These trials aim to evaluate the safety, efficacy, and optimal dosing of emavusertib, both as a monotherapy and in combination with other drugs, offering new hope for patients with relapsed or refractory forms of these challenging blood cancers.

Table of Contents

What is Emavusertib?

Emavusertib, also known as CA-4948, is a new drug being studied for the treatment of various blood cancers and lymphomas[1][2]. It is an oral medication, which means it can be taken by mouth in the form of tablets. Emavusertib is currently being tested in clinical trials to determine its effectiveness and safety in treating patients with certain types of cancer.

How Does Emavusertib Work?

Emavusertib is a novel small molecule inhibitor that targets a specific protein in the body called interleukin-1 receptor-associated kinase 4 (IRAK4)[1]. IRAK4 plays an important role in certain signaling pathways within cells, particularly in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways. These pathways are often overactive in some types of blood cancers and lymphomas, contributing to the growth and survival of cancer cells.

By inhibiting IRAK4, emavusertib aims to disrupt these signaling pathways, potentially slowing down or stopping the growth of cancer cells. This targeted approach is part of a new generation of cancer treatments that aim to be more specific and potentially less toxic than traditional chemotherapy.

What Conditions Does Emavusertib Treat?

Emavusertib is being studied for the treatment of several types of blood cancers and lymphomas, including:

  • Acute Myelogenous Leukemia (AML): A type of blood cancer that affects the bone marrow and blood[1]
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[1]
  • Primary Central Nervous System Lymphoma (PCNSL): A rare type of cancer that affects the brain and spinal cord[2]
  • Other relapsed or refractory hematologic malignancies: This refers to blood cancers that have either come back after treatment or did not respond well to initial treatments[2]

Current Clinical Trials

Emavusertib is currently being studied in several clinical trials:

  1. A Phase 1/2A study for patients with AML or MDS[1]. This study aims to:
    • Determine the safe dose of emavusertib
    • Assess how well the drug works in treating these conditions
    • Evaluate the drug’s safety profile
  2. A study for patients with relapsed or refractory hematologic malignancies, including PCNSL[2]. This study is:
    • Testing emavusertib alone and in combination with another drug called ibrutinib
    • Evaluating the safety and effectiveness of these treatments
    • Assessing how well emavusertib can penetrate the blood-brain barrier, which is important for treating cancers that affect the brain

How is Emavusertib Administered?

Emavusertib is given as an oral medication, typically in the form of tablets. In the clinical trials, it is being administered in the following ways:

  • Twice daily (BID) dosing[1][2]
  • In 28-day cycles[1]
  • The exact dose may vary depending on the specific trial and the patient’s response to the treatment

Combination Therapy

In some clinical trials, emavusertib is being studied in combination with other drugs:

  • Venetoclax: A drug that targets a protein called BCL-2, which helps cancer cells survive. This combination is being studied in patients with AML or MDS[1].
  • Ibrutinib: A drug used to treat certain types of blood cancers. This combination is being studied in patients with PCNSL[2].

These combinations are being tested to see if they can improve the effectiveness of treatment compared to using emavusertib alone.

Safety and Side Effects

As emavusertib is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring patients for any side effects or adverse reactions. Some of the key safety considerations include:

  • Dose-limiting toxicities (DLTs): These are side effects that are severe enough to prevent increasing the dose of the drug[1][2].
  • Maximum Tolerated Dose (MTD): This is the highest dose that can be given without causing unacceptable side effects[1][2].
  • Overall tolerability: The studies are assessing how well patients can tolerate the drug over time[1][2].

It’s important to note that as a participant in a clinical trial, patients are closely monitored for any side effects, and the treatment can be adjusted or stopped if necessary.

Aspect Details
Drug Name Emavusertib (CA-4948)
Mechanism of Action Inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4)
Target Conditions AML, MDS, R/R PCNSL
Administration Oral tablet, typically twice daily
Trial Phases Phase 1/2a
Study Objectives Safety, tolerability, optimal dosing, efficacy, pharmacokinetics
Combination Therapies Ibrutinib, Venetoclax (previous study)
Key Outcomes Measured MTD, RP2D, ORR, DOR, PFS, OS

FAQ

  • What is emavusertib and how does it work? Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). It works by targeting the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are often dysregulated in blood cancers like AML, MDS, and lymphomas.
  • What types of cancer is emavusertib being studied for? Emavusertib is being investigated for various hematologic malignancies, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).
  • How is emavusertib administered in clinical trials? Emavusertib is given as an oral tablet, typically taken twice daily (BID). The dosing schedule and duration may vary depending on the specific trial and whether it's used as a monotherapy or in combination with other drugs.
  • Are there any combinations being studied with emavusertib? Yes, some clinical trials are studying emavusertib in combination with other drugs. For example, it's being investigated in combination with ibrutinib for R/R PCNSL, and there was a previous study combining it with venetoclax for AML and MDS patients.
  • What are the main goals of the clinical trials involving emavusertib? The main goals of these trials include determining the safety and tolerability of emavusertib, finding the optimal dose (maximum tolerated dose and recommended Phase 2 dose), assessing its effectiveness in treating various blood cancers, and evaluating its pharmacokinetic profile (how the drug moves through the body).

Ongoing Clinical Trials on Emavusertib

  • A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

    Recruiting

    1 1 1
    Investigated drugs:
    Italy Spain

  • Study on the Safety of CA-4948 and Ibrutinib for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

    Recruiting

    1 1 1
    Investigated drugs:
    Czechia France Italy Poland Spain

  • Study of Emavusertib for Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Not recruiting

    1 1
    Investigated drugs:
    France Germany Spain

Glossary

  • Acute Myelogenous Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to various health problems and may progress to acute myeloid leukemia.
  • Primary Central Nervous System Lymphoma (PCNSL): A rare type of non-Hodgkin lymphoma that starts in the brain, spinal cord, or eyes.
  • Relapsed/Refractory (R/R): Refers to cancer that has returned after treatment (relapsed) or does not respond to initial treatment (refractory).
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be appropriate for further testing in Phase 2 clinical trials, based on safety and efficacy data from earlier studies.
  • Dose-Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.

References